2644-33-9

Basic information

• Product Name: 2-(diethylamino)acetohydrazide (non-preferred name)
• Synonyms: 2-(diethylamino)acetohydrazide
• CAS NO: 2644-33-9
• Molecular Formula: C₆H₁₅N₃O
• Molecular Weight: 145.2028
• Mol File: 2644-33-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 277.5°C at 760 mmHg
• Flash Point: 121.6°C
• Density: 1.005g/cm³
• Vapor Pressure: 0.00452mmHg at 25°C
• Refractive Index: 1.475
• CAS DataBase Reference: 2-(diethylamino)acetohydrazide (non-preferred name)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(diethylamino)acetohydrazide (non-preferred name)(2644-33-9)
• EPA Substance Registry System: 2-(diethylamino)acetohydrazide (non-preferred name)(2644-33-9)

Safety Data

• Hazardous Substances Data: 2644-33-9(Hazardous Substances Data)

Upstream product

• 2644-21-5 ethyl N,N-diethylglycinate 
• 30280-35-4 N,N-diethylglycine methyl ester 

Downstream Products

• 35819-96-6 Durolaldehyd-N,N-diethylamino-acethydrazon 
• 35819-91-1 2-Chlorbenzaldehyd-N,N-diethylaminoacethydrazon 
• 35819-89-7 3,4,5-Trimethoxybenzaldehyd-N,N-diethylamino-acethydrazon 
• 28744-17-4 4-Phenyl-1-diaethylaminoacetyl-semicarbazid 
• 35806-48-5 3,4-Dihydroxybenzaldehyd-N,N-diethylamino-acethydrazon 
• 5956-92-3 Diethylamino-acetic acid [2-biphenyl-4-yl-2-oxo-eth-(Z)-ylidene]-hydrazide 
• 19473-83-7 1-Benzoyl-<(α-diethylamino)-acetyl>-diaminoguanidin 
• 35806-51-0 Cyclohexancarboxaldehyd-N,N-diethylamino-acethydrazon 
• 35806-49-6 2-Nitrobenzaldehyd-N,N-diethylaminoacethydrazon 

Relevant articles and documents

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.